Based on our observation that PI3K activation is associated with higher levels of regulatory T cells, the development of PI3K inhibitors in combination with immunomodulatory agents that are able to deplete regulatory T cells might be of interest for luminal breast cancer [43]. The gene discussed is PIK3CA; the disease is breast carcinoma.